Overview

SimuGen is a venture-backed pharmacogenomics company focused on predicting human toxicity early on in drug development. The company combines groundbreaking human cell culture and genomic modelling to produce high throughput screens for use alongside other early ADME testing. SimuGen's software explicitly answers three important questions that guide decisions around a lead compound:

1. What toxicities does it produce?
2. How toxic is it?
3. What could be done to make it less toxic?

The flagship product will predict a wide spectrum of human liver safety concerns, a leading problem stifling drug innovation. However, the basic approach can assess multiple-organ toxicities. SimuGen's goal is to meet a major market gap that is not adequately addressed by current toxicogenomics - to accurately predict toxicity in the early stages of drug discovery/development.

The company was originally born in 2006 out of the talents of the Cambridge and Oxford technology clusters in the UK. In 2008 the company expanded into the Asia Pacific with the establishment of premises in Kuala Lumpur (Malaysia). SimuGen also has an office in London (UK) to retain close relationships with Europe's leading bioscience and technology pools.

"The problem is that current toxicogenomics approaches still need maturing and are expensive, slow, highly variable, often qualitative and do not easily yield information useful to decide whether to progress a drug candidate or not"